

NOVO NORDISK A S  
Form 6-K  
January 20, 2015  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

January 19, 2015

---

NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

Novo Allé  
DK- 2880, Bagsvaerd  
Denmark  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 19 January 2015 – On 30 October 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.

Under the programme initiated 30 October 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 30 October 2014 to 28 January 2015.

Since the announcement as of 12 January 2015, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	10,833,000		2,901,986,132
12 January 2015	230,000	273.50	62,903,896
13 January 2015	200,000	277.78	55,556,180
14 January 2015	275,000	278.50	76,588,380
15 January 2015	215,000	279.83	60,163,343
16 January 2015	250,000	281.88	70,469,075
Accumulated under the programme	12,003,000		3,227,667,006

With the transactions stated above, Novo Nordisk owns a total of 59,487,153 B shares of DKK 0.20, corresponding to 2.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 16 January 2015, Novo Nordisk has repurchased a total of 57,026,995 B shares equal to a transaction value of DKK 14,432,042,221.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), [Facebook](https://www.facebook.com/novonordisk), [Twitter](https://twitter.com/novonordisk), [LinkedIn](https://www.linkedin.com/company/novonordisk), [YouTube](https://www.youtube.com/user/novonordisk)

#### Further information

##### Media:

Anne Margrethe Hauge                    +45 3079 3450                    [amhg@novonordisk.com](mailto:amhg@novonordisk.com)

##### Investors:

Kasper Roseeuw Poulsen                +45 3079 4303                    [krop@novonordisk.com](mailto:krop@novonordisk.com)

Jannick Lindegaard Denholt            +45 3079 8519                    [jlis@novonordisk.com](mailto:jlis@novonordisk.com)

Daniel Bohsen                            +45 3079 6376                    [dabo@novonordisk.com](mailto:dabo@novonordisk.com)

Melanie Raouzeos                      +45 3075 3479                    [mrz@novonordisk.com](mailto:mrz@novonordisk.com)

Frank Daniel Mersebach (US)          +1 609 235 8567                    [fdni@novonordisk.com](mailto:fdni@novonordisk.com)

Novo Nordisk A/S  
Investor Relations

Novo Allé  
2880 Bagsværd  
Denmark

Telephone:  
+45 4444 8888

Internet:  
[www.novonordisk.com](http://www.novonordisk.com)  
CVR no:  
24 25 67 90

Company announcement No 3 / 2015

---

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: January 19, 2015

NOVO NORDISK A/S

Lars Rebien Sørensen,  
Chief Executive Officer